Biomarker-driven clinical trials are becoming more complex as precision medicine expands across therapeutic areas. Multi-analyte algorithms, blood-based assays, spatial biology and companion diagnostics are changing how patients are selected, monitored and stratified. This webinar will explore how precision biomarkers can support patient stratification, trial enrichment and clinical implementation.
A featured scientific case study will examine how multi-analyte biomarker strategies can improve patient stratification compared with single-marker approaches in Alzheimer’s disease, illustrating how multidimensional biological information may reduce diagnostic uncertainty, identify patients earlier in the disease continuum and support more effective clinical trial enrichment. Additional examples from spatial biology and companion diagnostic development will demonstrate how tissue biomarker workflows are also increasingly supporting precision medicine programs across therapeutic areas.
Attendees will gain practical insights into the operational requirements needed to transform emerging biomarker discoveries into trial-ready solutions, from assay development and validation through clinical implementation, while exploring how integrated laboratory partnerships can help reduce development risk, improve data quality and support successful execution of modern biomarker-driven clinical trials.
Register for this webinar to learn how precision biomarkers can improve patient stratification, clinical trial enrichment and trial-ready biomarker implementation.
Speaker
Jorge Marques Signes, PhD, Vice President, Laboratory Services, Quanterix
Dr. Jorge Marques Signes leads Quanterix’s Laboratory Services organization, overseeing translational biomarker development, custom assay development, clinical trial biomarker testing and regulated diagnostic laboratory operations. His organization integrates ultrasensitive blood biomarker platforms, spatial biology technologies and CLIA-compliant laboratory services to support pharmaceutical and biotechnology partners from early biomarker discovery through analytical validation, clinical development and diagnostic implementation.
With more than two decades of experience spanning molecular biology, biomarker development, laboratory operations and in vitro diagnostics, Dr. Marqués works with industry partners to operationalize biomarker strategies that accelerate precision medicine, improve clinical trial execution and enable the translation of innovative biomarkers into clinically actionable diagnostic solutions.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Clinical Development leaders
- Translational Medicine Scientists
- Biomarker Strategy teams
- Clinical Operations professionals
- Precision Medicine and Companion Diagnostic teams
- Medical Directors
- Clinical Laboratory Scientists
- Neuroscience Drug Development teams
- Oncology Translational Research teams
- Pharmaceutical and Biotechnology Program leaders
- CRO Scientific leadership
- Clinical Biomarker Directors
What You Will Learn
Attendees will learn:
- Why biomarker innovation increasingly depends on operational excellence, not analytical performance alone
- How multi-analyte biomarker strategies can improve patient stratification and clinical trial enrichment when compared with traditional single-marker approaches
- Best practices for translating discovery biomarkers into analytically validated trial-ready assays
- How blood-based biomarkers, spatial biology and regulatory-grade laboratory operations can support precision medicine across the clinical development continuum
Xtalks Partner
Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account